AFM-Téléthon renews its support to EspeRare's drug development efforts in Duchenne
Following AFM’s positive review of EspeRare’s plans to further develop Rimeporide in children affected with Duchenne muscular dystrophy (DMD), the french leading patient organization has renewed its financial support to EspeRare’s program. This grant will co-finance a biomarker study and partly the phase Ib clinical trial activities that are currently being initiated in several clinical centers in Europe. In the context of this additional commitment the French organization, pioneer in funding and supporting rare disease research, has also invited the Rimeporide program into its strategic portfolio. This will provide EspeRare a facilitated access to AFM’s network of biomedical experts and strategic guidance to best advance Rimeporide for boys burdened by such debilitating disease.
As a private non-for-profit organisation, we strive to uncover the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, thus giving better chances to existing drugs to reach these underserved patients.